Global Closed-loop Neuromodulation Systems Supply, Demand and Key Producers, 2026-2032

November 2026 | 130 pages | ID: GD48786400C4EN
GlobalInfoResearch

US$ 4,480.00

E-mail Delivery (PDF)

Download PDF Leaflet

Accepted cards
Wire Transfer
Checkout Later
Need Help? Ask a Question
The global Closed-loop Neuromodulation Systems market size is expected to reach $ 714 million by 2032, rising at a market growth of 8.7% CAGR during the forecast period (2026-2032).

Closed-loop Neuromodulation Systems are advanced medical device systems that combine neural stimulation, physiological signal sensing and feedback control algorithms to dynamically adjust stimulation parameters based on real-time patient responses. The systems typically consist of implantable pulse generators, neural electrodes, sensing modules, control algorithms and external programming platforms, enabling personalized neuromodulation therapy through adaptive stimulation. The market primarily covers fully implantable closed-loop systems applied in spinal cord stimulation, responsive neurostimulation and adaptive deep brain stimulation for the treatment of chronic pain, epilepsy, movement disorders and other neurological conditions. The research focuses on commercialized closed-loop neuromodulation platforms with integrated feedback and stimulation capabilities.

Key FindingsIn 2025, the global average selling price of commercial closed-loop neuromodulation systems was approximately US$28,000–35,000 per unit.The industry-wide gross margin was approximately 55%–75%.Fully implantable systems remained the dominant commercial product form.Closed-loop spinal cord stimulation systems remained the largest product category.Chronic pain management remained the largest clinical application.North America maintained the largest commercial demand base and the most mature level of clinical adoption.

Market Trends

The most important technology transition is from open-loop stimulation toward sensing-enabled, adaptive and increasingly personalized therapy. ECAP-based feedback has established a practical commercial pathway in spinal cord stimulation by measuring the neural response generated by stimulation and automatically adjusting output to maintain therapy within a targeted range. In brain stimulation, local field potential and other brain-signal sensing technologies are enabling adaptive DBS systems to modify therapy according to changing neural activity rather than relying solely on fixed clinician-programmed parameters.

Commercialization of adaptive DBS accelerated materially in 2025. Medtronic received CE Mark approval in January 2025 and U.S. FDA approval in February 2025 for BrainSense Adaptive DBS, which automatically adjusts stimulation using real-time brain signals; the company stated that more than 40,000 patients worldwide had already been treated with its sensing-enabled Percept platform. Responsive neurostimulation is another established closed-loop pathway: NeuroPace’s system continuously monitors brain activity and responds to patient-specific seizure patterns in real time. These developments indicate that closed-loop control is moving from a specialized feature toward a broader product-development direction across implantable neuromodulation.

Market Dynamics

Drivers

Growth is primarily supported by the continuing need for more consistent and personalized treatment of chronic pain and neurological disorders. Conventional stimulation can require repeated programming because neural responses vary with posture, disease progression, medication state and individual physiology. Closed-loop systems address this limitation by incorporating physiological feedback into therapy delivery, creating potential advantages in treatment consistency, programming efficiency and personalization. Chronic pain remains the largest demand base, while Parkinson’s disease, drug-resistant epilepsy and other neurological indications broaden the addressable clinical opportunity.

Technology improvements are also reducing barriers to adoption. Higher-performance implantable electronics, longer battery life, improved rechargeable pulse generators, lower-noise neural sensing and more sophisticated signal-processing algorithms are allowing sensing and stimulation functions to be integrated into increasingly compact platforms. Saluda Medical’s FDA-approved closed-loop SCS architecture, for example, senses spinal cord responses and automatically adjusts therapy, demonstrating the commercial viability of ECAP-controlled stimulation.

Restraints

High development expenditure, complex regulatory requirements and the need for long-term clinical evidence remain the principal market restraints. Manufacturers must establish not only the safety and reliability of the implanted hardware but also the robustness of sensing, signal interpretation and automated therapy adjustment. These requirements increase development time and cost relative to conventional stimulation systems. Reimbursement is another constraint because adoption of new neuromodulation technologies depends on procedure coverage, physician acceptance and evidence demonstrating incremental clinical value relative to established therapies.

Opportunities

Adaptive DBS is emerging as one of the most important incremental opportunities as sensing-enabled DBS platforms transition from monitoring brain signals to automatically adjusting therapy. Responsive stimulation for epilepsy remains another differentiated market in which continuous neural monitoring and event-triggered stimulation provide a clear closed-loop value proposition. Beyond these established applications, neurological rehabilitation, peripheral nerve stimulation and selected psychiatric indications could broaden the addressable market as clinical evidence develops.

Non-invasive and wearable closed-loop neuromodulation represents an additional emerging direction. Systems combining external stimulation with EEG, fNIRS or other physiological sensing may enable lower-risk and more accessible treatment pathways. However, these products currently differ significantly from fully implantable systems in clinical positioning, regulatory pathways, treatment intensity and commercial value, and therefore remain a smaller and less standardized portion of the broader closed-loop neuromodulation landscape.

Challenges

Signal quality and biological variability remain fundamental technical challenges. Neural signals are weak, highly patient-specific and susceptible to movement, electrical interference and changes in physiological state. A clinically useful closed-loop system must distinguish meaningful biomarkers from noise while preventing inappropriate stimulation adjustments. Long-term implant reliability, electrode stability, battery performance, cybersecurity and software validation add further engineering requirements.

Another challenge is clinical standardization. Closed-loop control strategies developed for chronic pain cannot be directly transferred to Parkinson’s disease or epilepsy because the relevant biomarkers, stimulation targets and therapeutic objectives differ substantially. Manufacturers therefore need disease-specific algorithms, clinical protocols and evidence packages, limiting the speed at which a single platform can expand across multiple indications.

Industry Chain Analysis

The upstream industry chain includes implantable-grade electronic components, batteries, hermetic packaging, stimulation and sensing ICs, neural electrodes, leads, connectors and biocompatible materials. Midstream manufacturers integrate these components into neurostimulators and combine them with sensing electronics, control algorithms, programming devices and patient data-management platforms. Downstream demand is concentrated in hospitals, neurosurgery centers, pain management centers and specialized neurological treatment institutions, with physicians and clinical support teams playing an important role in patient selection, implantation, programming and long-term follow-up.

The supply chain is characterized by stringent qualification requirements and relatively high switching costs. Implantable components must meet demanding reliability and biocompatibility requirements, while changes in electrodes, batteries, packaging or electronics may require extensive verification. As a result, established component relationships and vertically integrated design capabilities can provide important advantages for system manufacturers.

Value Chain Analysis

Value creation is concentrated less in basic assembly than in system integration, proprietary sensing technology, algorithms, regulatory assets and clinical evidence. Implantable pulse generators and electrodes remain major hardware value components, but the incremental premium associated with closed-loop systems increasingly comes from their ability to capture clinically relevant neural signals and transform those signals into safe, adaptive therapy.

The value chain is therefore moving toward a hardware-software-clinical integration model. Manufacturers with proprietary sensing platforms, large longitudinal neural datasets, disease-specific control algorithms and established physician-support networks are better positioned to improve treatment performance and defend product differentiation. Over time, software upgrades and data-driven therapy optimization are expected to become increasingly important contributors to system value.

Segment Insights

By product function, closed-loop spinal cord stimulation systems remain the largest commercial segment, with chronic pain providing the largest established patient base. Responsive neurostimulation forms a distinct segment centered on real-time detection and treatment of abnormal brain activity, while adaptive deep brain stimulation is entering a stronger commercialization phase as sensing-enabled DBS platforms transition toward automatic parameter adjustment. Other closed-loop neuromodulation approaches remain comparatively small and heterogeneous.

By product form, fully implantable systems remain the dominant category because they support continuous long-term therapy without permanent external connections. Semi-implantable systems have a more limited commercial role, while non-invasive and wearable systems remain an emerging category. By technology route, ECAP feedback is particularly important in closed-loop SCS, brain-signal feedback is central to adaptive DBS, and seizure-detection feedback defines responsive neurostimulation.

Downstream Market Opportunities

Chronic pain management remains the largest downstream opportunity because spinal cord stimulation already has an established clinical pathway and patient population, giving closed-loop SCS a clearer upgrade route from conventional stimulation. The principal opportunity is not simply expansion of overall SCS use, but increasing penetration of systems capable of maintaining therapy through continuous measurement and automatic adjustment.

Movement disorders and epilepsy provide the next major opportunity pools. Adaptive DBS can address fluctuations in neural activity associated with Parkinson’s disease and treatment state, while responsive neurostimulation offers a differentiated approach for selected patients with drug-resistant focal epilepsy. Longer term, neurological rehabilitation and other disorders involving identifiable physiological biomarkers may create additional opportunities, although commercialization will depend on indication-specific clinical evidence and reimbursement.

Regional Insights

North America remains the leading regional market in terms of commercialization, clinical adoption and availability of advanced closed-loop platforms. The region benefits from a mature implantable neuromodulation ecosystem, specialist physician networks, extensive clinical research infrastructure and established reimbursement channels. It also remains the principal commercialization market for closed-loop SCS and responsive neurostimulation.

Europe maintains a strong position in neuroengineering, clinical research and emerging adaptive stimulation technologies, although commercialization varies across healthcare systems. Asia Pacific represents the most important expansion region, supported by rising neurological treatment demand, expanding specialist healthcare capacity and increasing local development of implantable neuromodulation devices. China has established domestic capability in DBS and other implantable neurostimulation systems, providing a manufacturing and clinical foundation for future closed-loop development, while Japan and South Korea currently have fewer confirmed domestic commercial closed-loop system manufacturers.

Competitive Landscape Analysis

The global competitive landscape remains regionally concentrated. North America has the strongest commercial ecosystem, supported by established implantable-device manufacturers, specialist neurotechnology companies, regulatory experience and broad clinical infrastructure. Its advantage extends beyond hardware manufacturing to clinical evidence generation, physician training and long-term patient management, creating significant barriers for new entrants.

Europe plays a more specialized innovation role, particularly in adaptive stimulation and neuroengineering, while Asia Pacific is gradually strengthening through domestic implantable-device development and localized clinical capabilities. Regional competition is expected to increasingly depend on sensing accuracy, adaptive algorithm performance, reliability of implantable systems, regulatory execution and the ability to demonstrate clinically meaningful improvements over conventional open-loop therapy.

Report Scope

This report studies the global Closed-loop Neuromodulation Systems production, demand, key manufacturers, and key regions.

This report is a detailed and comprehensive analysis of the world market for Closed-loop Neuromodulation Systems and provides market size (US$ million) and Year-over-Year (YoY) Growth, considering 2025 as the base year. This report explores demand trends and competition, as well as details the characteristics of Closed-loop Neuromodulation Systems that contribute to its increasing demand across many markets.

Highlights and key features of the study

  • Global Closed-loop Neuromodulation Systems total production and demand, 2021-2032, (Units)
  • Global Closed-loop Neuromodulation Systems total production value, 2021-2032, (USD Million)
  • Global Closed-loop Neuromodulation Systems production by region & country, production, value, CAGR, 2021-2032, (USD Million) & (Units), (based on production site)
  • Global Closed-loop Neuromodulation Systems consumption by region & country, CAGR, 2021-2032 & (Units)
  • U.S. VS China: Closed-loop Neuromodulation Systems domestic production, consumption, key domestic manufacturers and share
  • Global Closed-loop Neuromodulation Systems production by manufacturer, production, price, value and market share 2021-2026, (USD Million) & (Units)
  • Global Closed-loop Neuromodulation Systems production by Type, production, value, CAGR, 2021-2032, (USD Million) & (Units)
  • Global Closed-loop Neuromodulation Systems production by Application, production, value, CAGR, 2021-2032, (USD Million) & (Units)
This report profiles key players in the global Closed-loop Neuromodulation Systems market based on the following parameters - company overview, production, value, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Medtronic plc, Abbott Laboratories, Boston Scientific Corporation, Saluda Medical Pty Ltd, Nevro Corp., NeuroPace, Inc., LivaNova PLC, Newronika S.p.A., PINS Medical Co., Ltd., SceneRay Co., Ltd., etc.

This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.

Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the World Closed-loop Neuromodulation Systems market

Detailed Segmentation:

Each section contains quantitative market data including market by value (US$ Millions), volume (production, consumption) & (Units) and average price (K US$/Unit) by manufacturer, by Type, and by Application. Data is given for the years 2021-2032 by year with 2025 as the base year, 2026 as the estimate year, and 2027-2032 as the forecast year.

Global Closed-loop Neuromodulation Systems Market, By Region:

  • United States
  • China
  • Europe
  • Japan
  • South Korea
  • ASEAN
  • India
  • Rest of World

Market Segmentation

Global Closed-loop Neuromodulation Systems Market, Segmentation by Type:

  • Fully Implantable Systems
  • Partially Implantable Systems
  • Non-Invasive Systems
  • Others

Global Closed-loop Neuromodulation Systems Market, Segmentation by Technology Route:

  • Evoked Compound Action Potential (ECAP) Feedback
  • Brain Signal Feedback Control
  • Seizure Detection Feedback
  • Others

Global Closed-loop Neuromodulation Systems Market, Segmentation by Stimulation Target:

  • Spinal Cord Stimulation
  • Brain Stimulation
  • Peripheral Nerve Stimulation
  • Vagus Nerve Stimulation
  • Others

Global Closed-loop Neuromodulation Systems Market, Segmentation by Application:

  • Chronic Pain Management
  • Movement Disorders
  • Epilepsy Treatment
  • Spinal Cord Injury Rehabilitation
  • Others

Companies Profiled:

  • Medtronic plc
  • Abbott Laboratories
  • Boston Scientific Corporation
  • Saluda Medical Pty Ltd
  • Nevro Corp.
  • NeuroPace, Inc.
  • LivaNova PLC
  • Newronika S.p.A.
  • PINS Medical Co., Ltd.
  • SceneRay Co., Ltd.
  • Changzhou Ruishen'an Medical Instrument Co., Ltd.
  • Nalu Medical Inc.
  • Axonics Inc.

Key Questions Answered

1. How big is the global Closed-loop Neuromodulation Systems market?
2. What is the demand of the global Closed-loop Neuromodulation Systems market?
3. What is the year over year growth of the global Closed-loop Neuromodulation Systems market?
4. What is the total value of the global Closed-loop Neuromodulation Systems market?
5. Who are the Major Players in the global Closed-loop Neuromodulation Systems market?
6. What are the growth factors driving the market demand?
1 SUPPLY SUMMARY

1.1 Closed-loop Neuromodulation Systems Introduction
1.2 World Closed-loop Neuromodulation Systems Supply & Forecast
  1.2.1 World Closed-loop Neuromodulation Systems Production Value (2021 & 2025 & 2032)
  1.2.2 World Closed-loop Neuromodulation Systems Production (2021-2032)
  1.2.3 World Closed-loop Neuromodulation Systems Pricing Trends (2021-2032)
1.3 World Closed-loop Neuromodulation Systems Production by Region (Based on Production Site)
  1.3.1 World Closed-loop Neuromodulation Systems Production Value by Region (2021-2032)
  1.3.2 World Closed-loop Neuromodulation Systems Production by Region (2021-2032)
  1.3.3 World Closed-loop Neuromodulation Systems Average Price by Region (2021-2032)
  1.3.4 North America Closed-loop Neuromodulation Systems Production (2021-2032)
  1.3.5 Europe Closed-loop Neuromodulation Systems Production (2021-2032)
  1.3.6 China Closed-loop Neuromodulation Systems Production (2021-2032)
1.4 Market Drivers, Restraints and Trends
  1.4.1 Closed-loop Neuromodulation Systems Market Drivers
  1.4.2 Factors Affecting Demand
  1.4.3 Closed-loop Neuromodulation Systems Major Market Trends

2 DEMAND SUMMARY

2.1 World Closed-loop Neuromodulation Systems Demand (2021-2032)
2.2 World Closed-loop Neuromodulation Systems Consumption by Region
  2.2.1 World Closed-loop Neuromodulation Systems Consumption by Region (2021-2026)
  2.2.2 World Closed-loop Neuromodulation Systems Consumption Forecast by Region (2027-2032)
2.3 United States Closed-loop Neuromodulation Systems Consumption (2021-2032)
2.4 China Closed-loop Neuromodulation Systems Consumption (2021-2032)
2.5 Europe Closed-loop Neuromodulation Systems Consumption (2021-2032)
2.6 Japan Closed-loop Neuromodulation Systems Consumption (2021-2032)
2.7 South Korea Closed-loop Neuromodulation Systems Consumption (2021-2032)
2.8 ASEAN Closed-loop Neuromodulation Systems Consumption (2021-2032)
2.9 India Closed-loop Neuromodulation Systems Consumption (2021-2032)

3 WORLD MANUFACTURERS COMPETITIVE ANALYSIS

3.1 World Closed-loop Neuromodulation Systems Production Value by Manufacturer (2021-2026)
3.2 World Closed-loop Neuromodulation Systems Production by Manufacturer (2021-2026)
3.3 World Closed-loop Neuromodulation Systems Average Price by Manufacturer (2021-2026)
3.4 Closed-loop Neuromodulation Systems Company Evaluation Quadrant
3.5 Industry Rank and Concentration Rate (CR)
  3.5.1 Global Closed-loop Neuromodulation Systems Industry Rank of Major Manufacturers
  3.5.2 Global Concentration Ratios (CR4) for Closed-loop Neuromodulation Systems in 2025
  3.5.3 Global Concentration Ratios (CR8) for Closed-loop Neuromodulation Systems in 2025
3.6 Closed-loop Neuromodulation Systems Market: Overall Company Footprint Analysis
  3.6.1 Closed-loop Neuromodulation Systems Market: Region Footprint
  3.6.2 Closed-loop Neuromodulation Systems Market: Company Product Type Footprint
  3.6.3 Closed-loop Neuromodulation Systems Market: Company Product Application Footprint
3.7 Competitive Environment
  3.7.1 Historical Structure of the Industry
  3.7.2 Barriers of Market Entry
  3.7.3 Factors of Competition
3.8 New Entrant and Capacity Expansion Plans
3.9 Mergers, Acquisition, Agreements, and Collaborations

4 UNITED STATES VS CHINA VS REST OF THE WORLD

4.1 United States VS China: Closed-loop Neuromodulation Systems Production Value Comparison
  4.1.1 United States VS China: Closed-loop Neuromodulation Systems Production Value Comparison (2021 & 2025 & 2032)
  4.1.2 United States VS China: Closed-loop Neuromodulation Systems Production Value Market Share Comparison (2021 & 2025 & 2032)
4.2 United States VS China: Closed-loop Neuromodulation Systems Production Comparison
  4.2.1 United States VS China: Closed-loop Neuromodulation Systems Production Comparison (2021 & 2025 & 2032)
  4.2.2 United States VS China: Closed-loop Neuromodulation Systems Production Market Share Comparison (2021 & 2025 & 2032)
4.3 United States VS China: Closed-loop Neuromodulation Systems Consumption Comparison
  4.3.1 United States VS China: Closed-loop Neuromodulation Systems Consumption Comparison (2021 & 2025 & 2032)
  4.3.2 United States VS China: Closed-loop Neuromodulation Systems Consumption Market Share Comparison (2021 & 2025 & 2032)
4.4 United States Based Closed-loop Neuromodulation Systems Manufacturers and Market Share, 2021-2026
  4.4.1 United States Based Closed-loop Neuromodulation Systems Manufacturers, Headquarters and Production Site (States, Country)
  4.4.2 United States Based Manufacturers Closed-loop Neuromodulation Systems Production Value (2021-2026)
  4.4.3 United States Based Manufacturers Closed-loop Neuromodulation Systems Production (2021-2026)
4.5 China Based Closed-loop Neuromodulation Systems Manufacturers and Market Share
  4.5.1 China Based Closed-loop Neuromodulation Systems Manufacturers, Headquarters and Production Site (Province, Country)
  4.5.2 China Based Manufacturers Closed-loop Neuromodulation Systems Production Value (2021-2026)
  4.5.3 China Based Manufacturers Closed-loop Neuromodulation Systems Production (2021-2026)
4.6 Rest of World Based Closed-loop Neuromodulation Systems Manufacturers and Market Share, 2021-2026
  4.6.1 Rest of World Based Closed-loop Neuromodulation Systems Manufacturers, Headquarters and Production Site (State, Country)
  4.6.2 Rest of World Based Manufacturers Closed-loop Neuromodulation Systems Production Value (2021-2026)
  4.6.3 Rest of World Based Manufacturers Closed-loop Neuromodulation Systems Production (2021-2026)

5 MARKET ANALYSIS BY TYPE

5.1 World Closed-loop Neuromodulation Systems Market Size Overview by Type: 2021 VS 2025 VS 2032
5.2 Segment Introduction by Type
  5.2.1 Fully Implantable Systems
  5.2.2 Partially Implantable Systems
  5.2.3 Non-Invasive Systems
  5.2.4 Others
5.3 Market Segment by Type
  5.3.1 World Closed-loop Neuromodulation Systems Production by Type (2021-2032)
  5.3.2 World Closed-loop Neuromodulation Systems Production Value by Type (2021-2032)
  5.3.3 World Closed-loop Neuromodulation Systems Average Price by Type (2021-2032)

6 MARKET ANALYSIS BY TECHNOLOGY ROUTE

6.1 World Closed-loop Neuromodulation Systems Market Size Overview by Technology Route: 2021 VS 2025 VS 2032
6.2 Segment Introduction by Technology Route
  6.2.1 Evoked Compound Action Potential (ECAP) Feedback
  6.2.2 Brain Signal Feedback Control
  6.2.3 Seizure Detection Feedback
  6.2.4 Others
6.3 Market Segment by Technology Route
  6.3.1 World Closed-loop Neuromodulation Systems Production by Technology Route (2021-2032)
  6.3.2 World Closed-loop Neuromodulation Systems Production Value by Technology Route (2021-2032)
  6.3.3 World Closed-loop Neuromodulation Systems Average Price by Technology Route (2021-2032)

7 MARKET ANALYSIS BY STIMULATION TARGET

7.1 World Closed-loop Neuromodulation Systems Market Size Overview by Stimulation Target: 2021 VS 2025 VS 2032
7.2 Segment Introduction by Stimulation Target
  7.2.1 Spinal Cord Stimulation
  7.2.2 Brain Stimulation
  7.2.3 Peripheral Nerve Stimulation
  7.2.4 Vagus Nerve Stimulation
  7.2.5 Others
7.3 Market Segment by Stimulation Target
  7.3.1 World Closed-loop Neuromodulation Systems Production by Stimulation Target (2021-2032)
  7.3.2 World Closed-loop Neuromodulation Systems Production Value by Stimulation Target (2021-2032)
  7.3.3 World Closed-loop Neuromodulation Systems Average Price by Stimulation Target (2021-2032)

8 MARKET ANALYSIS BY APPLICATION

8.1 World Closed-loop Neuromodulation Systems Market Size Overview by Application: 2021 VS 2025 VS 2032
8.2 Segment Introduction by Application
  8.2.1 Chronic Pain Management
  8.2.2 Movement Disorders
  8.2.3 Epilepsy Treatment
  8.2.4 Spinal Cord Injury Rehabilitation
  8.2.5 Others
8.3 Market Segment by Application
  8.3.1 World Closed-loop Neuromodulation Systems Production by Application (2021-2032)
  8.3.2 World Closed-loop Neuromodulation Systems Production Value by Application (2021-2032)
  8.3.3 World Closed-loop Neuromodulation Systems Average Price by Application (2021-2032)

9 COMPANY PROFILES

9.1 Medtronic plc
  9.1.1 Medtronic plc Details
  9.1.2 Medtronic plc Major Business
  9.1.3 Medtronic plc Closed-loop Neuromodulation Systems Product and Services
  9.1.4 Medtronic plc Closed-loop Neuromodulation Systems Production, Price, Value, Gross Margin and Market Share (2021-2026)
  9.1.5 Medtronic plc Recent Developments/Updates
  9.1.6 Medtronic plc Competitive Strengths & Weaknesses
9.2 Abbott Laboratories
  9.2.1 Abbott Laboratories Details
  9.2.2 Abbott Laboratories Major Business
  9.2.3 Abbott Laboratories Closed-loop Neuromodulation Systems Product and Services
  9.2.4 Abbott Laboratories Closed-loop Neuromodulation Systems Production, Price, Value, Gross Margin and Market Share (2021-2026)
  9.2.5 Abbott Laboratories Recent Developments/Updates
  9.2.6 Abbott Laboratories Competitive Strengths & Weaknesses
9.3 Boston Scientific Corporation
  9.3.1 Boston Scientific Corporation Details
  9.3.2 Boston Scientific Corporation Major Business
  9.3.3 Boston Scientific Corporation Closed-loop Neuromodulation Systems Product and Services
  9.3.4 Boston Scientific Corporation Closed-loop Neuromodulation Systems Production, Price, Value, Gross Margin and Market Share (2021-2026)
  9.3.5 Boston Scientific Corporation Recent Developments/Updates
  9.3.6 Boston Scientific Corporation Competitive Strengths & Weaknesses
9.4 Saluda Medical Pty Ltd
  9.4.1 Saluda Medical Pty Ltd Details
  9.4.2 Saluda Medical Pty Ltd Major Business
  9.4.3 Saluda Medical Pty Ltd Closed-loop Neuromodulation Systems Product and Services
  9.4.4 Saluda Medical Pty Ltd Closed-loop Neuromodulation Systems Production, Price, Value, Gross Margin and Market Share (2021-2026)
  9.4.5 Saluda Medical Pty Ltd Recent Developments/Updates
  9.4.6 Saluda Medical Pty Ltd Competitive Strengths & Weaknesses
9.5 Nevro Corp.
  9.5.1 Nevro Corp. Details
  9.5.2 Nevro Corp. Major Business
  9.5.3 Nevro Corp. Closed-loop Neuromodulation Systems Product and Services
  9.5.4 Nevro Corp. Closed-loop Neuromodulation Systems Production, Price, Value, Gross Margin and Market Share (2021-2026)
  9.5.5 Nevro Corp. Recent Developments/Updates
  9.5.6 Nevro Corp. Competitive Strengths & Weaknesses
9.6 NeuroPace, Inc.
  9.6.1 NeuroPace, Inc. Details
  9.6.2 NeuroPace, Inc. Major Business
  9.6.3 NeuroPace, Inc. Closed-loop Neuromodulation Systems Product and Services
  9.6.4 NeuroPace, Inc. Closed-loop Neuromodulation Systems Production, Price, Value, Gross Margin and Market Share (2021-2026)
  9.6.5 NeuroPace, Inc. Recent Developments/Updates
  9.6.6 NeuroPace, Inc. Competitive Strengths & Weaknesses
9.7 LivaNova PLC
  9.7.1 LivaNova PLC Details
  9.7.2 LivaNova PLC Major Business
  9.7.3 LivaNova PLC Closed-loop Neuromodulation Systems Product and Services
  9.7.4 LivaNova PLC Closed-loop Neuromodulation Systems Production, Price, Value, Gross Margin and Market Share (2021-2026)
  9.7.5 LivaNova PLC Recent Developments/Updates
  9.7.6 LivaNova PLC Competitive Strengths & Weaknesses
9.8 Newronika S.p.A.
  9.8.1 Newronika S.p.A. Details
  9.8.2 Newronika S.p.A. Major Business
  9.8.3 Newronika S.p.A. Closed-loop Neuromodulation Systems Product and Services
  9.8.4 Newronika S.p.A. Closed-loop Neuromodulation Systems Production, Price, Value, Gross Margin and Market Share (2021-2026)
  9.8.5 Newronika S.p.A. Recent Developments/Updates
  9.8.6 Newronika S.p.A. Competitive Strengths & Weaknesses
9.9 PINS Medical Co., Ltd.
  9.9.1 PINS Medical Co., Ltd. Details
  9.9.2 PINS Medical Co., Ltd. Major Business
  9.9.3 PINS Medical Co., Ltd. Closed-loop Neuromodulation Systems Product and Services
  9.9.4 PINS Medical Co., Ltd. Closed-loop Neuromodulation Systems Production, Price, Value, Gross Margin and Market Share (2021-2026)
  9.9.5 PINS Medical Co., Ltd. Recent Developments/Updates
  9.9.6 PINS Medical Co., Ltd. Competitive Strengths & Weaknesses
9.10 SceneRay Co., Ltd.
  9.10.1 SceneRay Co., Ltd. Details
  9.10.2 SceneRay Co., Ltd. Major Business
  9.10.3 SceneRay Co., Ltd. Closed-loop Neuromodulation Systems Product and Services
  9.10.4 SceneRay Co., Ltd. Closed-loop Neuromodulation Systems Production, Price, Value, Gross Margin and Market Share (2021-2026)
  9.10.5 SceneRay Co., Ltd. Recent Developments/Updates
  9.10.6 SceneRay Co., Ltd. Competitive Strengths & Weaknesses
9.11 Changzhou Ruishen'an Medical Instrument Co., Ltd.
  9.11.1 Changzhou Ruishen'an Medical Instrument Co., Ltd. Details
  9.11.2 Changzhou Ruishen'an Medical Instrument Co., Ltd. Major Business
  9.11.3 Changzhou Ruishen'an Medical Instrument Co., Ltd. Closed-loop Neuromodulation Systems Product and Services
  9.11.4 Changzhou Ruishen'an Medical Instrument Co., Ltd. Closed-loop Neuromodulation Systems Production, Price, Value, Gross Margin and Market Share (2021-2026)
  9.11.5 Changzhou Ruishen'an Medical Instrument Co., Ltd. Recent Developments/Updates
  9.11.6 Changzhou Ruishen'an Medical Instrument Co., Ltd. Competitive Strengths & Weaknesses
9.12 Nalu Medical Inc.
  9.12.1 Nalu Medical Inc. Details
  9.12.2 Nalu Medical Inc. Major Business
  9.12.3 Nalu Medical Inc. Closed-loop Neuromodulation Systems Product and Services
  9.12.4 Nalu Medical Inc. Closed-loop Neuromodulation Systems Production, Price, Value, Gross Margin and Market Share (2021-2026)
  9.12.5 Nalu Medical Inc. Recent Developments/Updates
  9.12.6 Nalu Medical Inc. Competitive Strengths & Weaknesses
9.13 Axonics Inc.
  9.13.1 Axonics Inc. Details
  9.13.2 Axonics Inc. Major Business
  9.13.3 Axonics Inc. Closed-loop Neuromodulation Systems Product and Services
  9.13.4 Axonics Inc. Closed-loop Neuromodulation Systems Production, Price, Value, Gross Margin and Market Share (2021-2026)
  9.13.5 Axonics Inc. Recent Developments/Updates
  9.13.6 Axonics Inc. Competitive Strengths & Weaknesses

10 INDUSTRY CHAIN ANALYSIS

10.1 Closed-loop Neuromodulation Systems Industry Chain
10.2 Closed-loop Neuromodulation Systems Upstream Analysis
  10.2.1 Closed-loop Neuromodulation Systems Core Raw Materials
  10.2.2 Main Manufacturers of Closed-loop Neuromodulation Systems Core Raw Materials
10.3 Midstream Analysis
10.4 Downstream Analysis
10.5 Closed-loop Neuromodulation Systems Production Mode
10.6 Closed-loop Neuromodulation Systems Procurement Model
10.7 Closed-loop Neuromodulation Systems Industry Sales Model and Sales Channels
  10.7.1 Closed-loop Neuromodulation Systems Sales Model
  10.7.2 Closed-loop Neuromodulation Systems Typical Distributors

11 RESEARCH FINDINGS AND CONCLUSION

12 APPENDIX

12.1 Methodology
12.2 Research Process and Data Source
12.3 Disclaimer
LIST OF TABLES

Table 1. World Closed-loop Neuromodulation Systems Production Value by Region (2021, 2025 and 2032) & (USD Million)
Table 2. World Closed-loop Neuromodulation Systems Production Value by Region (2021-2026) & (USD Million)
Table 3. World Closed-loop Neuromodulation Systems Production Value by Region (2027-2032) & (USD Million)
Table 4. World Closed-loop Neuromodulation Systems Production Value Market Share by Region (2021-2026)
Table 5. World Closed-loop Neuromodulation Systems Production Value Market Share by Region (2027-2032)
Table 6. World Closed-loop Neuromodulation Systems Production by Region (2021-2026) & (Units)
Table 7. World Closed-loop Neuromodulation Systems Production by Region (2027-2032) & (Units)
Table 8. World Closed-loop Neuromodulation Systems Production Market Share by Region (2021-2026)
Table 9. World Closed-loop Neuromodulation Systems Production Market Share by Region (2027-2032)
Table 10. World Closed-loop Neuromodulation Systems Average Price by Region (2021-2026) & (K US$/Unit)
Table 11. World Closed-loop Neuromodulation Systems Average Price by Region (2027-2032) & (K US$/Unit)
Table 12. Closed-loop Neuromodulation Systems Major Market Trends
Table 13. World Closed-loop Neuromodulation Systems Consumption Growth Rate Forecast by Region (2021 & 2025 & 2032) & (Units)
Table 14. World Closed-loop Neuromodulation Systems Consumption by Region (2021-2026) & (Units)
Table 15. World Closed-loop Neuromodulation Systems Consumption Forecast by Region (2027-2032) & (Units)
Table 16. World Closed-loop Neuromodulation Systems Production Value by Manufacturer (2021-2026) & (USD Million)
Table 17. Production Value Market Share of Key Closed-loop Neuromodulation Systems Producers in 2025
Table 18. World Closed-loop Neuromodulation Systems Production by Manufacturer (2021-2026) & (Units)
Table 19. Production Market Share of Key Closed-loop Neuromodulation Systems Producers in 2025
Table 20. World Closed-loop Neuromodulation Systems Average Price by Manufacturer (2021-2026) & (K US$/Unit)
Table 21. Global Closed-loop Neuromodulation Systems Company Evaluation Quadrant
Table 22. World Closed-loop Neuromodulation Systems Industry Rank of Major Manufacturers, Based on Production Value in 2025
Table 23. Head Office and Closed-loop Neuromodulation Systems Production Site of Key Manufacturer
Table 24. Closed-loop Neuromodulation Systems Market: Company Product Type Footprint
Table 25. Closed-loop Neuromodulation Systems Market: Company Product Application Footprint
Table 26. Closed-loop Neuromodulation Systems Competitive Factors
Table 27. Closed-loop Neuromodulation Systems New Entrant and Capacity Expansion Plans
Table 28. Closed-loop Neuromodulation Systems Mergers & Acquisitions Activity
Table 29. United States VS China Closed-loop Neuromodulation Systems Production Value Comparison, (2021 & 2025 & 2032) & (USD Million)
Table 30. United States VS China Closed-loop Neuromodulation Systems Production Comparison, (2021 & 2025 & 2032) & (Units)
Table 31. United States VS China Closed-loop Neuromodulation Systems Consumption Comparison, (2021 & 2025 & 2032) & (Units)
Table 32. United States Based Closed-loop Neuromodulation Systems Manufacturers, Headquarters and Production Site (States, Country)
Table 33. United States Based Manufacturers Closed-loop Neuromodulation Systems Production Value, (2021-2026) & (USD Million)
Table 34. United States Based Manufacturers Closed-loop Neuromodulation Systems Production Value Market Share (2021-2026)
Table 35. United States Based Manufacturers Closed-loop Neuromodulation Systems Production (2021-2026) & (Units)
Table 36. United States Based Manufacturers Closed-loop Neuromodulation Systems Production Market Share (2021-2026)
Table 37. China Based Closed-loop Neuromodulation Systems Manufacturers, Headquarters and Production Site (Province, Country)
Table 38. China Based Manufacturers Closed-loop Neuromodulation Systems Production Value, (2021-2026) & (USD Million)
Table 39. China Based Manufacturers Closed-loop Neuromodulation Systems Production Value Market Share (2021-2026)
Table 40. China Based Manufacturers Closed-loop Neuromodulation Systems Production, (2021-2026) & (Units)
Table 41. China Based Manufacturers Closed-loop Neuromodulation Systems Production Market Share (2021-2026)
Table 42. Rest of World Based Closed-loop Neuromodulation Systems Manufacturers, Headquarters and Production Site (State, Country)
Table 43. Rest of World Based Manufacturers Closed-loop Neuromodulation Systems Production Value, (2021-2026) & (USD Million)
Table 44. Rest of World Based Manufacturers Closed-loop Neuromodulation Systems Production Value Market Share (2021-2026)
Table 45. Rest of World Based Manufacturers Closed-loop Neuromodulation Systems Production, (2021-2026) & (Units)
Table 46. Rest of World Based Manufacturers Closed-loop Neuromodulation Systems Production Market Share (2021-2026)
Table 47. World Closed-loop Neuromodulation Systems Production Value by Type, (USD Million), 2021 & 2025 & 2032
Table 48. World Closed-loop Neuromodulation Systems Production by Type (2021-2026) & (Units)
Table 49. World Closed-loop Neuromodulation Systems Production by Type (2027-2032) & (Units)
Table 50. World Closed-loop Neuromodulation Systems Production Value by Type (2021-2026) & (USD Million)
Table 51. World Closed-loop Neuromodulation Systems Production Value by Type (2027-2032) & (USD Million)
Table 52. World Closed-loop Neuromodulation Systems Average Price by Type (2021-2026) & (K US$/Unit)
Table 53. World Closed-loop Neuromodulation Systems Average Price by Type (2027-2032) & (K US$/Unit)
Table 54. World Closed-loop Neuromodulation Systems Production Value by Technology Route, (USD Million), 2021 & 2025 & 2032
Table 55. World Closed-loop Neuromodulation Systems Production by Technology Route (2021-2026) & (Units)
Table 56. World Closed-loop Neuromodulation Systems Production by Technology Route (2027-2032) & (Units)
Table 57. World Closed-loop Neuromodulation Systems Production Value by Technology Route (2021-2026) & (USD Million)
Table 58. World Closed-loop Neuromodulation Systems Production Value by Technology Route (2027-2032) & (USD Million)
Table 59. World Closed-loop Neuromodulation Systems Average Price by Technology Route (2021-2026) & (K US$/Unit)
Table 60. World Closed-loop Neuromodulation Systems Average Price by Technology Route (2027-2032) & (K US$/Unit)
Table 61. World Closed-loop Neuromodulation Systems Production Value by Stimulation Target, (USD Million), 2021 & 2025 & 2032
Table 62. World Closed-loop Neuromodulation Systems Production by Stimulation Target (2021-2026) & (Units)
Table 63. World Closed-loop Neuromodulation Systems Production by Stimulation Target (2027-2032) & (Units)
Table 64. World Closed-loop Neuromodulation Systems Production Value by Stimulation Target (2021-2026) & (USD Million)
Table 65. World Closed-loop Neuromodulation Systems Production Value by Stimulation Target (2027-2032) & (USD Million)
Table 66. World Closed-loop Neuromodulation Systems Average Price by Stimulation Target (2021-2026) & (K US$/Unit)
Table 67. World Closed-loop Neuromodulation Systems Average Price by Stimulation Target (2027-2032) & (K US$/Unit)
Table 68. World Closed-loop Neuromodulation Systems Production Value by Application, (USD Million), 2021 & 2025 & 2032
Table 69. World Closed-loop Neuromodulation Systems Production by Application (2021-2026) & (Units)
Table 70. World Closed-loop Neuromodulation Systems Production by Application (2027-2032) & (Units)
Table 71. World Closed-loop Neuromodulation Systems Production Value by Application (2021-2026) & (USD Million)
Table 72. World Closed-loop Neuromodulation Systems Production Value by Application (2027-2032) & (USD Million)
Table 73. World Closed-loop Neuromodulation Systems Average Price by Application (2021-2026) & (K US$/Unit)
Table 74. World Closed-loop Neuromodulation Systems Average Price by Application (2027-2032) & (K US$/Unit)
Table 75. Medtronic plc Basic Information, Manufacturing Base and Competitors
Table 76. Medtronic plc Major Business
Table 77. Medtronic plc Closed-loop Neuromodulation Systems Product and Services
Table 78. Medtronic plc Closed-loop Neuromodulation Systems Production (Units), Price (K US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 79. Medtronic plc Recent Developments/Updates
Table 80. Medtronic plc Competitive Strengths & Weaknesses
Table 81. Abbott Laboratories Basic Information, Manufacturing Base and Competitors
Table 82. Abbott Laboratories Major Business
Table 83. Abbott Laboratories Closed-loop Neuromodulation Systems Product and Services
Table 84. Abbott Laboratories Closed-loop Neuromodulation Systems Production (Units), Price (K US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 85. Abbott Laboratories Recent Developments/Updates
Table 86. Abbott Laboratories Competitive Strengths & Weaknesses
Table 87. Boston Scientific Corporation Basic Information, Manufacturing Base and Competitors
Table 88. Boston Scientific Corporation Major Business
Table 89. Boston Scientific Corporation Closed-loop Neuromodulation Systems Product and Services
Table 90. Boston Scientific Corporation Closed-loop Neuromodulation Systems Production (Units), Price (K US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 91. Boston Scientific Corporation Recent Developments/Updates
Table 92. Boston Scientific Corporation Competitive Strengths & Weaknesses
Table 93. Saluda Medical Pty Ltd Basic Information, Manufacturing Base and Competitors
Table 94. Saluda Medical Pty Ltd Major Business
Table 95. Saluda Medical Pty Ltd Closed-loop Neuromodulation Systems Product and Services
Table 96. Saluda Medical Pty Ltd Closed-loop Neuromodulation Systems Production (Units), Price (K US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 97. Saluda Medical Pty Ltd Recent Developments/Updates
Table 98. Saluda Medical Pty Ltd Competitive Strengths & Weaknesses
Table 99. Nevro Corp. Basic Information, Manufacturing Base and Competitors
Table 100. Nevro Corp. Major Business
Table 101. Nevro Corp. Closed-loop Neuromodulation Systems Product and Services
Table 102. Nevro Corp. Closed-loop Neuromodulation Systems Production (Units), Price (K US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 103. Nevro Corp. Recent Developments/Updates
Table 104. Nevro Corp. Competitive Strengths & Weaknesses
Table 105. NeuroPace, Inc. Basic Information, Manufacturing Base and Competitors
Table 106. NeuroPace, Inc. Major Business
Table 107. NeuroPace, Inc. Closed-loop Neuromodulation Systems Product and Services
Table 108. NeuroPace, Inc. Closed-loop Neuromodulation Systems Production (Units), Price (K US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 109. NeuroPace, Inc. Recent Developments/Updates
Table 110. NeuroPace, Inc. Competitive Strengths & Weaknesses
Table 111. LivaNova PLC Basic Information, Manufacturing Base and Competitors
Table 112. LivaNova PLC Major Business
Table 113. LivaNova PLC Closed-loop Neuromodulation Systems Product and Services
Table 114. LivaNova PLC Closed-loop Neuromodulation Systems Production (Units), Price (K US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 115. LivaNova PLC Recent Developments/Updates
Table 116. LivaNova PLC Competitive Strengths & Weaknesses
Table 117. Newronika S.p.A. Basic Information, Manufacturing Base and Competitors
Table 118. Newronika S.p.A. Major Business
Table 119. Newronika S.p.A. Closed-loop Neuromodulation Systems Product and Services
Table 120. Newronika S.p.A. Closed-loop Neuromodulation Systems Production (Units), Price (K US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 121. Newronika S.p.A. Recent Developments/Updates
Table 122. Newronika S.p.A. Competitive Strengths & Weaknesses
Table 123. PINS Medical Co., Ltd. Basic Information, Manufacturing Base and Competitors
Table 124. PINS Medical Co., Ltd. Major Business
Table 125. PINS Medical Co., Ltd. Closed-loop Neuromodulation Systems Product and Services
Table 126. PINS Medical Co., Ltd. Closed-loop Neuromodulation Systems Production (Units), Price (K US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 127. PINS Medical Co., Ltd. Recent Developments/Updates
Table 128. PINS Medical Co., Ltd. Competitive Strengths & Weaknesses
Table 129. SceneRay Co., Ltd. Basic Information, Manufacturing Base and Competitors
Table 130. SceneRay Co., Ltd. Major Business
Table 131. SceneRay Co., Ltd. Closed-loop Neuromodulation Systems Product and Services
Table 132. SceneRay Co., Ltd. Closed-loop Neuromodulation Systems Production (Units), Price (K US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 133. SceneRay Co., Ltd. Recent Developments/Updates
Table 134. SceneRay Co., Ltd. Competitive Strengths & Weaknesses
Table 135. Changzhou Ruishen'an Medical Instrument Co., Ltd. Basic Information, Manufacturing Base and Competitors
Table 136. Changzhou Ruishen'an Medical Instrument Co., Ltd. Major Business
Table 137. Changzhou Ruishen'an Medical Instrument Co., Ltd. Closed-loop Neuromodulation Systems Product and Services
Table 138. Changzhou Ruishen'an Medical Instrument Co., Ltd. Closed-loop Neuromodulation Systems Production (Units), Price (K US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 139. Changzhou Ruishen'an Medical Instrument Co., Ltd. Recent Developments/Updates
Table 140. Changzhou Ruishen'an Medical Instrument Co., Ltd. Competitive Strengths & Weaknesses
Table 141. Nalu Medical Inc. Basic Information, Manufacturing Base and Competitors
Table 142. Nalu Medical Inc. Major Business
Table 143. Nalu Medical Inc. Closed-loop Neuromodulation Systems Product and Services
Table 144. Nalu Medical Inc. Closed-loop Neuromodulation Systems Production (Units), Price (K US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 145. Nalu Medical Inc. Recent Developments/Updates
Table 146. Nalu Medical Inc. Competitive Strengths & Weaknesses
Table 147. Axonics Inc. Basic Information, Manufacturing Base and Competitors
Table 148. Axonics Inc. Major Business
Table 149. Axonics Inc. Closed-loop Neuromodulation Systems Product and Services
Table 150. Axonics Inc. Closed-loop Neuromodulation Systems Production (Units), Price (K US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 151. Axonics Inc. Recent Developments/Updates
Table 152. Axonics Inc. Competitive Strengths & Weaknesses
Table 153. Global Key Players of Closed-loop Neuromodulation Systems Upstream (Raw Materials)
Table 154. Global Closed-loop Neuromodulation Systems Typical Customers
Table 155. Closed-loop Neuromodulation Systems Typical Distributors

LIST OF FIGURES

Figure 1. Closed-loop Neuromodulation Systems Picture
Figure 2. World Closed-loop Neuromodulation Systems Production Value: 2021 & 2025 & 2032, (USD Million)
Figure 3. World Closed-loop Neuromodulation Systems Production Value and Forecast (2021-2032) & (USD Million)
Figure 4. World Closed-loop Neuromodulation Systems Production (2021-2032) & (Units)
Figure 5. World Closed-loop Neuromodulation Systems Average Price (2021-2032) & (K US$/Unit)
Figure 6. World Closed-loop Neuromodulation Systems Production Value Market Share by Region (2021-2032)
Figure 7. World Closed-loop Neuromodulation Systems Production Market Share by Region (2021-2032)
Figure 8. North America Closed-loop Neuromodulation Systems Production (2021-2032) & (Units)
Figure 9. Europe Closed-loop Neuromodulation Systems Production (2021-2032) & (Units)
Figure 10. China Closed-loop Neuromodulation Systems Production (2021-2032) & (Units)
Figure 11. Closed-loop Neuromodulation Systems Market Drivers
Figure 12. Factors Affecting Demand
Figure 13. World Closed-loop Neuromodulation Systems Consumption (2021-2032) & (Units)
Figure 14. World Closed-loop Neuromodulation Systems Consumption Market Share by Region (2021-2032)
Figure 15. United States Closed-loop Neuromodulation Systems Consumption (2021-2032) & (Units)
Figure 16. China Closed-loop Neuromodulation Systems Consumption (2021-2032) & (Units)
Figure 17. Europe Closed-loop Neuromodulation Systems Consumption (2021-2032) & (Units)
Figure 18. Japan Closed-loop Neuromodulation Systems Consumption (2021-2032) & (Units)
Figure 19. South Korea Closed-loop Neuromodulation Systems Consumption (2021-2032) & (Units)
Figure 20. ASEAN Closed-loop Neuromodulation Systems Consumption (2021-2032) & (Units)
Figure 21. India Closed-loop Neuromodulation Systems Consumption (2021-2032) & (Units)
Figure 22. Producer Shipments of Closed-loop Neuromodulation Systems by Manufacturer Revenue ($MM) and Market Share (%): 2025
Figure 23. Global Four-firm Concentration Ratios (CR4) for Closed-loop Neuromodulation Systems Markets in 2025
Figure 24. Global Four-firm Concentration Ratios (CR8) for Closed-loop Neuromodulation Systems Markets in 2025
Figure 25. United States VS China: Closed-loop Neuromodulation Systems Production Value Market Share Comparison (2021 & 2025 & 2032)
Figure 26. United States VS China: Closed-loop Neuromodulation Systems Production Market Share Comparison (2021 & 2025 & 2032)
Figure 27. United States VS China: Closed-loop Neuromodulation Systems Consumption Market Share Comparison (2021 & 2025 & 2032)
Figure 28. United States Based Manufacturers Closed-loop Neuromodulation Systems Production Market Share 2025
Figure 29. China Based Manufacturers Closed-loop Neuromodulation Systems Production Market Share 2025
Figure 30. Rest of World Based Manufacturers Closed-loop Neuromodulation Systems Production Market Share 2025
Figure 31. World Closed-loop Neuromodulation Systems Production Value by Type, (USD Million), 2021 & 2025 & 2032
Figure 32. World Closed-loop Neuromodulation Systems Production Value Market Share by Type in 2025
Figure 33. Fully Implantable Systems
Figure 34. Partially Implantable Systems
Figure 35. Non-Invasive Systems
Figure 36. Others
Figure 37. World Closed-loop Neuromodulation Systems Production Market Share by Type (2021-2032)
Figure 38. World Closed-loop Neuromodulation Systems Production Value Market Share by Type (2021-2032)
Figure 39. World Closed-loop Neuromodulation Systems Average Price by Type (2021-2032) & (K US$/Unit)
Figure 40. World Closed-loop Neuromodulation Systems Production Value by Technology Route, (USD Million), 2021 & 2025 & 2032
Figure 41. World Closed-loop Neuromodulation Systems Production Value Market Share by Technology Route in 2025
Figure 42. Evoked Compound Action Potential (ECAP) Feedback
Figure 43. Brain Signal Feedback Control
Figure 44. Seizure Detection Feedback
Figure 45. Others
Figure 46. World Closed-loop Neuromodulation Systems Production Market Share by Technology Route (2021-2032)
Figure 47. World Closed-loop Neuromodulation Systems Production Value Market Share by Technology Route (2021-2032)
Figure 48. World Closed-loop Neuromodulation Systems Average Price by Technology Route (2021-2032) & (K US$/Unit)
Figure 49. World Closed-loop Neuromodulation Systems Production Value by Stimulation Target, (USD Million), 2021 & 2025 & 2032
Figure 50. World Closed-loop Neuromodulation Systems Production Value Market Share by Stimulation Target in 2025
Figure 51. Spinal Cord Stimulation
Figure 52. Brain Stimulation
Figure 53. Peripheral Nerve Stimulation
Figure 54. Vagus Nerve Stimulation
Figure 55. Others
Figure 56. World Closed-loop Neuromodulation Systems Production Market Share by Stimulation Target (2021-2032)
Figure 57. World Closed-loop Neuromodulation Systems Production Value Market Share by Stimulation Target (2021-2032)
Figure 58. World Closed-loop Neuromodulation Systems Average Price by Stimulation Target (2021-2032) & (K US$/Unit)
Figure 59. World Closed-loop Neuromodulation Systems Production Value by Application, (USD Million), 2021 & 2025 & 2032
Figure 60. World Closed-loop Neuromodulation Systems Production Value Market Share by Application in 2025
Figure 61. Chronic Pain Management
Figure 62. Movement Disorders
Figure 63. Epilepsy Treatment
Figure 64. Spinal Cord Injury Rehabilitation
Figure 65. Others
Figure 66. World Closed-loop Neuromodulation Systems Production Market Share by Application (2021-2032)
Figure 67. World Closed-loop Neuromodulation Systems Production Value Market Share by Application (2021-2032)
Figure 68. World Closed-loop Neuromodulation Systems Average Price by Application (2021-2032) & (K US$/Unit)
Figure 69. Closed-loop Neuromodulation Systems Industry Chain
Figure 70. Closed-loop Neuromodulation Systems Procurement Model
Figure 71. Closed-loop Neuromodulation Systems Sales Model
Figure 72. Closed-loop Neuromodulation Systems Sales Channels, Direct Sales, and Distribution
Figure 73. Methodology
Figure 74. Research Process and Data Source